B-cell lymphoma

9 trials 3 recruiting MedDRA PT
9 Registered trials
3 Recruiting
8 Unique sponsors
9 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (rat) 1 substance
CAR-T cell therapy 1 substance
CDK inhibitor 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 2 Phase II: 2 Phase I/II: 2 Phase I: 3

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

2 trials
  • Novartis Pharma Services AG Commercial
    AUTOLOGOUS T-CELLS ENCODING A CHIMERIC ANTIGEN RECEPTOR TARGETING HUMAN B CELL MATURATION ANTIGEN; RAPCABTAGENE AUTOLEUCEL
    2023-508128-37-00 12 countries 2017 n=222
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2025-521571-30-00 1 country n=228
    Pending

Phase II

2 trials
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2024-511747-25-00 5 countries 2019 n=225 Orphan
    Ended
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic
    GLOFITAMAB; OBINUTUZUMAB; POLATUZUMAB VEDOTIN; RITUXIMAB
    2024-513949-37-00 2 countries 2023 n=126
    Ended

Phase I/II

2 trials
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Cyclacel Limited Commercial
    CYC140 MONOHYDROCHLORIDE MONOHYDRATE
    2024-516290-67-00 1 country 2022 n=56
    Ended

Phase I

3 trials
  • Immunome Inc. Commercial
    IMP not specified
    2025-523160-20-00 4 countries 2026 n=41
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
  • Step Pharma Academic
    IMP not specified
    2022-502299-21-00 1 country 2023 n=85
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Cyclacel Limited Commercial 2 Phase I/II 0
Immunome Inc. Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase II 0
Novartis Pharma Services AG Commercial 1 Phase III 1
Step Pharma Academic 1 Phase I 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 1 Phase II 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III 0
New trials by year
2019
1
2022
2
2023
2
2024
1
2026
1
← All indication landscapes